evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

8 questions · 8 findings · 1 reviews · Musculoskeletal

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 37.5%Moderate 2 · 25%High 3 · 37.5%

Chondroitin vs placebo

Pain on a 0 to 100 scale ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis
1 finding from 1 review

Chondroitin vs placebo

WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis

Chondroitin leads to higher WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term… compared with placebo (high certainty).

1 finding from 1 review

Chondroitin vs placebo

Radiographic Outcome: Reduction in Minimum Joint Space Width (JSW) in mm ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d Scale: millimeters (smaller decrease in reduction in minimum joint space width is better) · patients with osteoarthritis
1 finding from 1 review

Chondroitin with or without glucosamine vs placebo or control

WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis

Chondroitin with or without glucosamine leads to higher WOMAC MCII Pain subscale (reduction in knee pain by 20%) Long‐term… compared with placebo/control (high certainty).

1 finding from 1 review